Estimating historical impacts of vaccination against influenza B/Yamagata in the United States to inform possible risks of re-emergence in the absence of vaccination

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S. 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from 2016/17–2019/20 by combining B/Yamagata prevalence data with model-based estimates of disease burden prevented by vaccination against all influenza B viruses. B/Yamagata comprised approximately 16–22% of positive virus specimens in 2016/17 and 2017/18, compared to 1% in 2018/19 and 2019/20. Across all seasons, we estimated that vaccination against B/Yamagata prevented 4.15 million illnesses, 58,500 hospitalizations, and 4,070 deaths, and that 22.9 million B/Yamagata-associated illnesses, 340,000 hospitalizations, and 25,100 deaths would have occurred without vaccination. Vaccination prevented the most B/Yamagata hospitalizations among adults ≥65 years but prevented the greatest percentage of B/Yamagata hospitalizations among children 6 months–4 years. Our results may help assess the potential impact if B/Yamagata were to recirculate in the absence of vaccination.

Article activity feed